BioSpace News Archive

Biotech Beach

Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research & Development Authority for Development of OPNT003 for the Treatment of Opioid Overdose

Opiant intends to pursue a 505(b)(2) development path for OPNT003 and anticipates the potential to submit a New Drug Application for the drug and intranasal delivery device combination in the fourth quarter 2020.

December 12, 2019
·
3 min read
Pharm Country

Therap’s Two Factor Authentication (2FA) Adds Additional Layer of Security

Organizations Using Web-Based Software Can Now Enable Enhanced Security Features to Address Technological Safeguards

December 12, 2019
·
2 min read
Business

MiMedx Provides Update Regarding Timing of Restatement

MiMedx Group, Inc. announced that it expects to file its annual report on Form 10-K for the years ended December 31, 2018, 2017 and 2016 in early 2020.

December 12, 2019
·
2 min read
Business

Universal Display Corporation Announces the Appointment of New Board Members

These new additions will expand Universal Display’s board to 9 members.

December 12, 2019
·
5 min read
Alberta’s biosimilars policy: another significant step towards improving patient access to safe, effective, and high-quality medicines in Canada

The province’s biosimilars policy could contribute to important healthcare savings

December 12, 2019
·
4 min read
McCann Health Dominates Specialist Agency Category In Campaign Asia-Pacific’s 2019 Agency Of The Year Awards

McCann Health Japan, India and Greater China Won a Total of 3 Golds

December 12, 2019
·
2 min read
Policy

MedTruth Launches Petition to Demand J&J to Add Warning Label to Talcum Powder Products

Yet many consumers are unaware of talcum powder’s dark history, and the potential risk of ovarian cancer it poses to the women using it daily.

December 12, 2019
·
2 min read
FDA

FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation

It is estimated that about 8 percent of patients with DMD have this mutation.

December 12, 2019
·
5 min read
Genetown

Oxford Recognized as #1 in Overall Satisfaction in the KLAS ERP Consulting 2019 Performance Report

Rated as a Top-Performer for a Staff Augmentation/Technical Services Firm

December 12, 2019
·
3 min read
FDA

Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

VYONDYS 53 is Sarepta’s second RNA exon-skipping treatment for DMD approved in the U.S.

December 12, 2019
·
12 min read